Market Research Report

Latin America Breast Cancer Therapeutics Market Research Report: Forecast (2024-2030)

Latin America Breast Cancer Therapeutics Market Report - By Drug Therapy (Chemotherapy Drug, (Anthracyclines, Taxanes, Antimetabolites, Others (Alkylating Agents, Epothilones, etc....)), Hormone Therapy (Selective Estrogen-Receptor Modulators (SERMs), Aromatase Inhibitors, Others (Zoladex, Faslodex, etc.)), Targeted Therapy, (Monoclonal Antibodies, Small Molecule Inhibitors, (Tyrosine Kinase Inhibitor, PI3K Inhibitors, Others (HER2 Kinase Inhibitors, etc.))), Others (Immunotherapy, Radiation Therapy, etc.), By Type of Cancer (Invasive (Infiltrating) Ductal Carcinoma (IDC), Lobular Breast Cancer, Ductal Carcinoma in Situ (DCIS), Others (Triple-Negative Breast Cancer (TNBC), Inflammatory Breast Cancer (IBC), etc.) and Others Read more

  • Healthcare
  • Feb 2024
  • 157
  • HC22139

Market Definition

The term "breast cancer therapeutics" refers to the variety of medical procedures and treatments used to manage and fight breast cancer. Depending on the cancer's stage, nature, and characteristics, these therapies include a variety of modalities, including surgery, chemotherapy, radiation therapy, hormone therapy, targeted therapy, and immunotherapy. These modalities are frequently used in combination. Breast cancer therapies aim to decrease tumor size, stop cancer from spreading or returning, relieve symptoms, and eventually increase patient quality of life and survival rates.

Market Insights & Analysis: Latin America Breast Cancer Therapeutics Market (2024-30):

The Latin America Breast Cancer Therapeutics Market size is estimated to grow at a CAGR of around 8.12% during the forecast period, i.e., 2024–30. Breast cancer continues to pose a significant health challenge in Latin America, with rising incidence rates driving the demand for effective treatment options. In 2022, breast cancer was the leading cause of cancer deaths in women in Latin America. Around 114,900 women were diagnosed, and nearly 37,000 women die of breast cancer every year in this region, as per the American Cancer Society. Thus, to overcome this, the region's breast cancer therapeutics market is witnessing notable advancements, fueled by increasing healthcare infrastructure and rising awareness among individuals.

Report Coverage Details
Study Period Historical Data: 2019-22
Base Year: 2023
Forecast Period: 2024-30
CAGR (2024-2030) 8.12%
Country Covered Brazil, Mexico, Argentina, Chile, Colombia, Peru, Rest of Latin America
Key Companies Profiled AstraZeneca Plc, Eisai Co., Ltd., Pfizer, Novartis, Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Genentech, Inc., MacroGenics, Inc., Others
Unit Denominations USD Million

 

In addition, the Latin America Breast Cancer Therapeutics Market is witnessing significant advancements in treatment options, including chemotherapy, targeted therapy, immunotherapy, and hormonal therapy. Pharmaceutical companies are introducing innovative drugs and biologics tailored to target specific molecular pathways involved in breast cancer progression, improving treatment efficacy and patient outcomes.

Moreover, increasing healthcare expenditures, the growing adoption of novel therapies, and government initiatives to improve cancer care are common factors in the Latin American region. For instance, according to the Organization for Economic Co-operation and Development, in 2023, Cuba allocated the highest percentage of its GDP to healthcare spending, approximately 11.1%, surpassing both Brazil and Argentina. With these favorable conditions, the Latin America Breast Cancer Therapeutics Market is likely to experience sustained growth, offering opportunities for pharmaceutical companies and healthcare providers to meet the rising demand for effective treatments and improve patient outcomes across the region.


Latin America Breast Cancer Therapeutics Market Research Report: Forecast (2024-2030)

Latin America Breast Cancer Therapeutics Market Driver:

Rising Incidence of Breast Cancer Across the Region – Latin America is experiencing an increase in the incidence of breast cancer, driven by factors such as population growth, aging demographics, lifestyle changes, and improved cancer detection and reporting. This growing disease burden is fueling demand for breast cancer therapeutics in the region. For instance,

  • According to the Pan American Health Organization, in 2020, there were more than 210,000 new diagnoses of breast cancer in Latin America and the Caribbean and nearly 68,000 deaths.

Hence, with the growing number of breast cancer cases, there is a corresponding increase in the demand for effective cancer therapeutics. Patients seek access to advanced treatment options to improve survival rates, enhance quality of life, and minimize adverse effects. Moreover, advancements in cancer research, including the development of novel drug therapies and personalized treatment approaches, are expanding the treatment landscape for breast cancer in Latin America. Consequently, the increasing number of clinical trials and research collaborations contributes to the introduction of innovative therapeutics that cater to the specific needs of patients in Latin America, positively influencing the breast cancer therapeutics industry in the region.

Latin America Breast Cancer Therapeutics Market Opportunity:

The Introduction of Telemedicine & Digital Health Solutions to Open New Doors – The adoption of telemedicine and digital health solutions is rising in Latin America, particularly in remote and underserved areas, which is expected to enhance the market size in the coming years. Pharmaceutical companies develop digital health tools, mobile applications, and telemedicine platforms to support patient education, adherence to treatment, and remote monitoring, thereby improving outcomes for breast cancer patients across the region.

Furthermore, telemedicine platforms and digital health tools generate valuable data on patient outcomes, treatment responses, and healthcare utilization patterns. Pharmaceutical companies control this data to gain insights into real-world treatment effectiveness, identify patients’ needs, and optimize their product development. Developing innovative digital tools and collaborating with healthcare providers offer flourishing opportunities for the growth & expansion of the Latin America Breast Cancer Therapeutics Market.

Latin America Breast Cancer Therapeutics Market Challenge:

Lack of Standardized Screening Protocols and Inadequate Diagnostic Resources – Without proper standardized screening protocols, many cases of breast cancer in Latin America are not detected until later stages, when the disease is more advanced and treatment options are limited. This delay in diagnosis reduces the effectiveness of therapeutic interventions and leads to poorer treatment outcomes for patients. In addition, late-stage diagnosis poses challenges for disease management and treatment planning across the region. Patients with advanced breast cancer require more aggressive treatment modalities, such as chemotherapy or targeted therapy, which could be associated with increased toxicity and adverse effects. Hence, the delayed diagnosis of breast cancer in Latin America negatively impacts the breast cancer therapeutics industry by reducing the number of patients eligible for early-stage treatments, such as surgery or hormone therapy.

Latin America Breast Cancer Therapeutics Market Trend:

Increasing Adoption of Personalized Medicine Approaches, such as Biomarker Testing & Genomic Profiling – In recent years, the healthcare sector has witnessed a remarkable upsurge in the adoption of personalized medicine approaches, such as biomarker testing & genomic profiling, to fight breast cancer. Biomarker testing and genomic profiling enable oncologists to identify specific molecular characteristics of a patient's tumor, allowing for more precise treatment selection. This personalized approach ensures that patients receive therapies that are likely to be effective for their particular type of breast cancer, improving treatment outcomes. Hence, by identifying biomarkers such as HER2 status, hormone receptor expression (estrogen receptor and progesterone receptor), and genetic mutations (e.g., BRCA1/2), healthcare providers can easily modify treatment regimens to target specific molecular pathways driving tumor growth.

This optimization of therapeutic strategies leads to improved efficacy and reduced risk of treatment resistance, which is anticipated to boost the market size in the forthcoming years. This trend of innovation in personalized medicine in the Latin America Breast Cancer Therapeutics Market is expected to prevail in the forecast period as well.

Latin America Breast Cancer Therapeutics Market (2024-30): Segmentation Analysis

The Latin America Breast Cancer Therapeutics study of MarkNtel Advisors evaluates & highlights the major trends and influencing factors in each segment. It includes predictions for the period 2024–2030 at the regional level. According to the analysis, the market has been further classified as:

Based on Drug Therapy:

  • Chemotherapy Drug
  • Anthracyclines
  • Taxanes
  • Antimetabolites
  • Others (Alkylating Agents, Epothilones, etc.)
  • Hormone Therapy
  • Selective Estrogen-Receptor Modulators (SERMs)
  • Aromatase Inhibitors
  • Others (Zoladex, Faslodex, etc.)
  • Targeted Therapy
  • Monoclonal Antibodies
  • Small Molecule Inhibitors
    • Tyrosine Kinase Inhibitor
    • PI3K Inhibitors
    • Others (HER2 Kinase Inhibitors, etc.)
  • Others (Immunotherapy, Radiation Therapy, etc.)

Chemotherapy remains a cornerstone of breast cancer treatment in Latin America, particularly for patients with advanced or metastatic disease, as well as those with certain subtypes of breast cancer that are more aggressive or hormone receptor-negative. It is often used in combination with other modalities such as surgery, radiation therapy, and targeted therapies. In addition, traditional cytotoxic chemotherapy agents continue to be widely used in Latin America, and there is also a growing interest in the development and adoption of newer, more targeted chemotherapy drugs and treatment approaches. Due to these developments, the chemotherapy segment is expected to hold a significant market share of the Latin America Breast Cancer Therapeutics Market during the forecast period.

Based on Type of Cancer:

  • Invasive (Infiltrating) Ductal Carcinoma (IDC)
  • Lobular Breast Cancer
  • Ductal Carcinoma in Situ (DCIS)
  • Others (Triple-Negative Breast Cancer (TNBC), Inflammatory Breast Cancer (IBC), etc.)

Invasive (Infiltrating) Ductal Carcinoma (IDC) is the most common type of breast cancer, comprising a significant portion of breast cancer cases diagnosed in Latin America. The treatment of IDC in Latin America involves a multimodal approach combining surgery, chemotherapy, radiation therapy, hormone therapy, and targeted therapies. The specific treatment procedure mainly depends on factors such as tumor stage, hormone receptor status, HER2 expression, patient age, and overall health status. Furthermore, increasing clinical research to advance the understanding of IDC biology, identify novel therapeutic targets, and develop more effective and personalized treatments is further expected to propel market growth during 2024–2030.

Latin America Breast Cancer Therapeutics Market (2024-30): Regional Projections

Geographically, the Latin America Breast Cancer Therapeutics Market expands across:

  • Brazil
  • Mexico
  • Argentina
  • Chile
  • Colombia
  • Peru
  • Rest of Latin America

Brazil acquired the largest market share in the Latin Breast Cancer Therapeutics Market in the historical years on the back of its massive population suffering from breast cancer. Additionally, growing awareness of breast cancer across the country and the increased prevalence of obesity contribute to an increasing requirement for breast cancer therapeutics in Brazil. For instance,

  • In Brazil, the National Cancer Institute (INCA) estimates that there were approximately 66,280 new cases of breast cancer annually between 2020 and 2022. Over this period, breast cancer emerged as the leading cancer type among Brazilian women, constituting 29.7% of total cases.

Hence, it evolved as an endemic disease across the country, amplifying the need for the development & approval of breast cancer treatments. Since Brazil has the highest number of breast cancer cases, the extensive presence of leading pharmaceutical & biotech companies and their various R&D activities in effective diagnosis & treatment are driving the market. The government is also spreading awareness among consumers through campaigns & other mediums about breast cancer & the extensive availability of its therapeutics across Brazil. Moreover, favorable norms for conducting clinical trials of novel drugs further provide bright opportunities for market expansion in the country.

Gain a Competitive Edge with Our Latin America Breast Cancer Therapeutics Market Report

  1. Latin America Breast Cancer Therapeutics Market Report by MarkNtel Advisors provides a detailed & thorough analysis of market size & market share, growth rate, competitive landscape, and key players. This comprehensive analysis helps businesses gain a holistic understanding of market dynamics & make informed decisions.
  2. This report also highlights current market trends & future projections, allowing businesses to identify emerging opportunities & potential challenges. By understanding market forecasts, companies can align their strategies & stay ahead of the competition.
  3. Latin America Breast Cancer Therapeutics Market Report aids in assessing & mitigating risks associated with entering or operating in the market. By understanding market dynamics, regulatory frameworks, and potential challenges, businesses can develop strategies to minimize risks & optimize their operations.

Frequently Asked Questions

   A. The Latin America Breast Cancer Therapeutics Market is expected to grow at a compound annual growth rate (CAGR) of around 8.12% over the forecast period.

   A. The rising incidence of breast cancer across the region is expected to drive the Latin America Breast Cancer Therapeutics Market during 2024-30.

   A. AstraZeneca Plc, Eisai Co., Ltd., Pfizer, Novartis, Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Genentech, Inc., MacroGenics, Inc., and others are the top companies in the Latin America Breast Cancer Therapeutics Market.

   A. The chemotherapy drug held the largest share of the Latin America Breast Cancer Therapeutics Market.

   A. Brazil would present growth prospects in the Latin America Breast Cancer Therapeutics Market during 2024-30.

   A. The increasing adoption of personalized medicine approaches, such as biomarker testing & genomic profiling, is the key trend shaping the growth of the Latin America Breast Cancer Therapeutics Market.

   A. The introduction of telemedicine & digital health solutions are the growth opportunities driving the Latin America Breast Cancer Therapeutics Market.

  1. Market Segmentation
  2. Introduction
    1. Market Definition
    2. Research Process
    3. Assumption
  3. Executive Summary
  4. Latin America Breast Cancer Therapeutics Market Trends & Insights
  5. Latin America Breast Cancer Therapeutics Market Dynamics
    1. Growth Drivers
    2. Challenges
  6. Latin America Breast Cancer Therapeutics Market Hotspot and Opportunities
  7. Latin America Breast Cancer Therapeutics Market Regulation & Policy, By Country
  8. Latin America Breast Cancer Therapeutics Market Outlook, 2019- 2030
    1. Market Size and Analysis
      1. By Revenues (USD Million)
    2. Market Share and Analysis
      1. By Drug Therapy
        1. Chemotherapy Drug- Market Size & Forecast 2019-2030, USD Million
          1. Anthracyclines- Market Size & Forecast 2019-2030, USD Million
          2. Taxanes- Market Size & Forecast 2019-2030, USD Million
          3. Antimetabolites- Market Size & Forecast 2019-2030, USD Million
          4. Others (Alkylating Agents, Epothilones, etc.) - Market Size & Forecast 2019-2030, USD Million
        2. Hormone Therapy
          1. Selective Estrogen-Receptor Modulators (SERMs)- Market Size & Forecast 2019-2030, USD Million
          2. Aromatase Inhibitors- Market Size & Forecast 2019-2030, USD Million
          3. Others (Zoladex, Faslodex, etc.)- Market Size & Forecast 2019-2030, USD Million
        3. Targeted Therapy
          1. Monoclonal Antibodies- Market Size & Forecast 2019-2030, USD Million
          2. Small Molecule Inhibitors- Market Size & Forecast 2019-2030, USD Million
            1. Tyrosine Kinase Inhibitor- Market Size & Forecast 2019-2030, USD Million
            2. PI3K Inhibitors- Market Size & Forecast 2019-2030, USD Million
            3. Others (HER2 Kinase Inhibitors, etc.)- Market Size & Forecast 2019-2030, USD Million
        4. Others (Immunotherapy, Radiation Therapy, etc.)- Market Size & Forecast 2019-2030, USD Million
      2. By Type of Cancer
        1. Invasive (Infiltrating) Ductal Carcinoma (IDC)- Market Size & Forecast 2019-2030, USD Million
        2. Lobular Breast Cancer- Market Size & Forecast 2019-2030, USD Million
        3. Ductal Carcinoma in Situ (DCIS)- Market Size & Forecast 2019-2030, USD Million
        4. Others (Triple-Negative Breast Cancer (TNBC), Inflammatory Breast Cancer (IBC), etc.)- Market Size & Forecast 2019-2030, USD Million
      3. By Country
        1. Brazil
        2. Mexico
        3. Argentina
        4. Chile
        5. Colombia
        6. Peru
        7. Rest of Latin America
      4. By Company
        1. Competition Characteristics
        2. Revenue Shares
  9. Brazil Breast Cancer Therapeutics Market Outlook, 2019- 2030
    1. Market Size and Analysis
      1. By Revenues (USD Million)
    2. Market Share and Analysis
      1. By Drug Therapy- Market Size & Forecast 2019-2030, (USD Million)
      2. By Type of Cancer- Market Size & Forecast 2019-2030, (USD Million)
  10. Mexico Breast Cancer Therapeutics Market Outlook, 2019- 2030
    1. Market Size and Analysis
      1. By Revenues (USD Million)
    2. Market Share and Analysis
      1. By Drug Therapy- Market Size & Forecast 2019-2030, (USD Million)
      2. By Type of Cancer- Market Size & Forecast 2019-2030, (USD Million)
  11. Argentina Breast Cancer Therapeutics Market Outlook, 2019- 2030
    1. Market Size and Analysis
      1. By Revenues (USD Million)
    2. Market Share and Analysis
      1. By Drug Therapy- Market Size & Forecast 2019-2030, (USD Million)
      2. By Type of Cancer- Market Size & Forecast 2019-2030, (USD Million)
  12. Chile Breast Cancer Therapeutics Market Outlook, 2019- 2030
    1. Market Size and Analysis
      1. By Revenues (USD Million)
    2. Market Share and Analysis
      1. By Drug Therapy- Market Size & Forecast 2019-2030, (USD Million)
      2. By Type of Cancer- Market Size & Forecast 2019-2030, (USD Million)
  13. Colombia Breast Cancer Therapeutics Market Outlook, 2019- 2030
    1. Market Size and Analysis
      1. By Revenues (USD Million)
    2. Market Share and Analysis
      1. By Drug Therapy- Market Size & Forecast 2019-2030, (USD Million)
      2. By Type of Cancer- Market Size & Forecast 2019-2030, (USD Million)
  14. Peru Breast Cancer Therapeutics Market Outlook, 2019- 2030
    1. Market Size and Analysis
      1. By Revenues (USD Million)
    2. Market Share and Analysis
      1. By Drug Therapy- Market Size & Forecast 2019-2030, (USD Million)
      2. By Type of Cancer- Market Size & Forecast 2019-2030, (USD Million)
  15. Latin America Breast Cancer Therapeutics Market Key Strategic Imperatives for Success and Growth
  16. Competitive Outlook
    1. Company Profiles
      1. AstraZeneca Plc
        1. Business Description
        2. Product Portfolio
        3. Strategic Alliances or Partnerships
        4. Recent Developments
        5. Financial Details
        6. Others
      2. Eisai Co., Ltd.
        1. Business Description
        2. Product Portfolio
        3. Strategic Alliances or Partnerships
        4. Recent Developments
        5. Financial Details
        6. Others
      3. Pfizer
        1. Business Description
        2. Product Portfolio
        3. Strategic Alliances or Partnerships
        4. Recent Developments
        5. Financial Details
        6. Others
      4. Novartis
        1. Business Description
        2. Product Portfolio
        3. Strategic Alliances or Partnerships
        4. Recent Developments
        5. Financial Details
        6. Others
      5. Bristol-Myers Squibb Company
        1. Business Description
        2. Product Portfolio
        3. Strategic Alliances or Partnerships
        4. Recent Developments
        5. Financial Details
        6. Others
      6. F. Hoffmann-La Roche Ltd.
        1. Business Description
        2. Product Portfolio
        3. Strategic Alliances or Partnerships
        4. Recent Developments
        5. Financial Details
        6. Others
      7. Merck & Co., Inc.
        1. Business Description
        2. Product Portfolio
        3. Strategic Alliances or Partnerships
        4. Recent Developments
        5. Financial Details
        6. Others
      8. Eli Lilly and Company
        1. Business Description
        2. Product Portfolio
        3. Strategic Alliances or Partnerships
        4. Recent Developments
        5. Financial Details
        6. Others
      9. Teva Pharmaceutical Industries Ltd.
        1. Business Description
        2. Product Portfolio
        3. Strategic Alliances or Partnerships
        4. Recent Developments
        5. Financial Details
        6. Others
      10. Genentech, Inc.
        1. Business Description
        2. Product Portfolio
        3. Strategic Alliances or Partnerships
        4. Recent Developments
        5. Financial Details
        6. Others
      11. MacroGenics, Inc.
        1. Business Description
        2. Product Portfolio
        3. Strategic Alliances or Partnerships
        4. Recent Developments
        5. Financial Details
        6. Others
      12. Others
  17. Disclaimer


Latin America Breast Cancer Therapeutics Market